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A central goal of developmental biology
is to understand the mechanisms whereby
undifferentiated, pluripotent cells differen-
tiate into mature, organized cells and
tissues. Recent advances in mouse genet-
ics, embryonic stem cell manipulation,
RNA inhibition, and genomics have now
made it possible to explore these mecha-
nisms with an unprecedented level of
resolution. One major class of proteins,
the chromodomain helicase DNA-binding
(CHD) family of ATP-dependent chroma-
tin remodelers, has emerged as important
regulators of cellular differentiation. CHD
proteins are thought to function in the
nucleus via binding to DNA and regulat-
ing gene transcription. CHD7, a member
of the CHD family, encodes a protein
mutated in human CHARGE syndrome,
a multiple anomaly disorder that affects
hearing, vision, and cardiac, craniofacial,
and nervous system development [1,2].
Previous reports have shown tissue and
developmental stage specific expression of
CHD7 [3,4], and there is evidence that
CHD7 binds thousands of sites in the
genome [5]. It is thus a major chal-
lenge to identify specific mechanisms of
CHD7 action in pluripotency versus
differentiation.
A study in this issue of PLoS Genetics [6]
used genomics approaches to explore
CHD7 binding sites and interacting part-
ners in embryonic stem (ES) cells. The
authors applied chromatin immunoprecip-
itation followed by next generation se-
quencing (ChIP-Seq) in ES cells under
several different growth conditions. They
found 10,483 chromatin sites bound by
CHD7, most of which appear to be
enhancer regions. CHD7 co-localized at
these sites with potentially unique combi-
nations of other DNA binding proteins,
including p300, Oct4, Sox2, Nanog,
Smad1, and STAT3 (see Table 1 for a
list of genes and their official symbols; for
the purposes of this Review, genes are
referred to as cited in the original papers).
In addition, genes directly regulated by
CHD7 were subtly downregulated in ES
cells, and these genes were far more ES
cell–specific than either genes that did not
change or those that decreased upon loss
of CHD7. Despite the predominance of
CHD7 binding sites in ES cell–specific
genes, ES cell pluripotency, self-renewal,
and reprogramming did not appear sensi-
tive to CHD7 dosage. Thus, CHD7 seems
to act as a rheostat of ES cell–specific gene
expression without overtly controlling ES
cell function.
Like ES cells, neural crest–derived cells
are pluripotent, since they differentiate
into numerous cell types including cranio-
facial mesenchyme, heart, peripheral ner-
vous system, and melanocytes. It has long
been proposed that neural crest abnor-
malities contribute to the pathophysiology
of CHARGE syndrome, but this had not
been directly tested. In a related study,
Bajpai et al. [7] explored CHD7 function
in Xenopus, and found that CHD7 is vital
for proper migration of neural crest in
developing branchial arches. They also
showed that human ES cells form a
pluripotent population of cells that express
markers of neural crest and can migrate to
craniofacial mesenchyme and heart after
transplantation into the chick neural tube.
Migration of these neural crest–like cells
(NCLCs) in vitro was also sensitive to
CHD7 dosage. The authors concluded
that CHD7 likely regulates cell migration
in the developing neural crest.
Because CHD7 binds to thousands of
enhancer sites in specific tissues during
development, it is possible that each site
binds a unique protein complex whose
composition changes over developmental
time. Identification and characterization
of these complexes is thus akin to separat-
ing the wheat (binding sites and complexes
that have functional significance) from the
chaff (binding sites and complexes that
have no functional significance). In the
paper by Schnetz et al., the ‘‘wheat’’
appears to be a set of about six factors
(Smad1, Nanog, Oct4, Sox2, Stat3, and
p300) that co-localize with CHD7 (based
on ChIP-Seq data) at specific DNA
binding sites called multiple transcription
factor loci or ‘‘MTLs’’ [6] (Figure 1).
Schnetz et al. also identified overlap
between sites occupied by BRG1 and
CHD7 in ES cells; however, the binding
was not as extensive as for the other six
factors [6]. Earlier data showed that
BRG1 associates with OCT4, SOX2,
and NANOG in ES cells [8], providing
further support for the idea that CHD7
binding in ES cells may be generally
associated with positive and negative
regulation. In the study by Bajpai et al.,
the ‘‘wheat’’ comprises the BAF and PBAF
chromatin remodeling complexes that
belong to the SWI/SNF family [7]. They
found, by co-immunoprecipitation in hu-
man NCLCs, that CHD7 binds numerous
PBAF specific subunits, including BRG1,
BAF170, BAF155, BAF57, PB1, ARID2,
and BRD7 (see Table 1 for official
symbols). Interestingly, a previous report
showed that CHD7 forms a complex with
SETDB1, NLK, and PPAR-gamma that
binds to DNA in a Wnt-5a responsive
manner and promotes Runx2 transcrip-
tion during osteoblast formation [9].
It is interesting to compare these recent
and earlier studies for evidence of CHD7
function in pluripotency versus cellular
fate determination and differentiation.
CHD7 does not appear to regulate
pluripotency in mouse ES cells [6] or
human NCLCs [7], but is required for
normal proliferation of olfactory neural
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promote one or more aspects of cellular
differentiation. Binding of CHD7-contain-
ing complexes activates osteoblast fates
over chondrocyte or myocyte differentia-
tion of bone marrow mesenchymal stem
cells [9] and promotes migration of neural
crest cells in the branchial arches [7].
These observations suggest multiple roles
Table 1. List of genes cited in the text and their official symbols.
Official Symbol Protein Type Aliases (mouse)
Ep300 E1A binding protein p300 KAT3B, p300
Pou5f1 POU class 5 homeobox 1 Oct-3, Oct-4, Otf-3, Otf-4
Sox2 SRY-box containing gene 2 Sox-2, lcc, ysb
Nanog Nanog homeobox ENK, ecat4
Smad1 MAD homolog 1 (Drosophila) Madh1, Madr1, Mlp1, MusMLP
Stat3 Signal transducer and activator of transcription 3 Aprf
Smarca4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily a, member 4
Brg1, HP1-BP72, SNF2beta, SW1/SNF
Smarcc2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily c, member 2
BRG1-associated factor 170; BAF170
Smarcc1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily c, member 1
BRG1-associated factor 155; BAF155, Rsc8, SRG3
Smarce1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily e, member 1
BAF57; BRG1-associated factor 57
Pbrm1 Polybromo 1 Pb1; BAF180; Pbrm1
Arid2 AT rich interactive domain 2 (ARID, RFX-like) zipzap/p200
Brd7 Bromodomain containing 7 BP75, CELTIX1, Ptpn13ip
Setdb1 SET domain, bifurcated 1 ESET, KMT1E
NLK Nemo like kinase AI194375
Pparg Peroxisome proliferator activated receptor gamma Nr1c3
Wnt5a Wingless-related MMTV integration site 5A Wnt-5a
Runx2 Runt related transcription factor 2 Cbfa1
*Genes in bold are aliases used in the cited references. Gene symbols are in reference to the mouse genome.
doi:10.1371/journal.pgen.1001010.t001
Figure 1. Cell type–specific DNA binding complexes containing CHD7. Proposed functions for CHD7 include cell motility and fate decisions.
These functions appear to be unique to specific stem cell populations. Hatched lines around BRG1 in ES cells indicate that only some of the
complexes have this protein as a component.
doi:10.1371/journal.pgen.1001010.g001
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genitor proliferation and/or differentiation
(Figure 2). Further investigation is neces-
sary to clarify whether CHD7 has similar
or different roles in the various cell types in
which it is expressed.
CHD7 and related proteins likely have
unique functions in human development.
Along with CHD7 and the other eight
CHD family members, there are about 30
mammalian genes encoding ATP-depen-
dent chromatin remodeling proteins [11].
ATP-dependent chromatin remodelers
differ from other chromatin modifiers
(which control DNA methylation and
histone acetylation) in that they are
genetically non-redundant, haploinsuffi-
cient, and increase nucleosome mobility
[11]. There are many human develop-
mental disorders known to result from
mutations in chromatin modifying pro-
teins, including Rubinstein-Taybi (CBP
and EP300), X-linked Alpha Thalassemia
(ATRX), and Rett Syndrome (MECP2),
among others [12]. Besides CHD7 and
CHARGE syndrome, there are few
developmental disorders known to result
from mutations in ATP dependent re-
modeling genes. Loss of CHD5 may
contribute to the microcephaly and phys-
ical features observed in Deletion 1p36
Syndrome [13], although its role is not yet
established. Deletion of WSTF (a member
of the ISWI class of ATP-dependent
chromatin remodelers), along with several
other genes in the critical interval on
chromosome 7q11, results in Williams-
Beuren syndrome, which presents with
cardiac defects, craniofacial dysmor-
phisms, and developmental/cognitive im-
pairments [14].
Accurate identification of CHD7 gene
targets, interacting partners, binding sites,
and complex subunit composition is going
to require cooperative, detailed studies
using high-throughput approaches and
model organisms. One could argue that
each cell type in a given tissue might have
unique CHD7 binding sites and protein
complexes that change over time. Finding
these is a daunting task, and it seems
more likely that common factors, targets,
and molecular genetic pathways will
emerge. It will be of great interest to
know, for example, whether CHD7
regulates specific signaling pathways dur-
ing organogenesis and whether those
pathways can be manipulated by molec-
ular intervention. In addition, there is no
information yet on CHD7 protein do-
main-specific functions, over-expression
phenotypes, or potential roles for CHD7
in cancer or aging. These topics are sure
to occupy researchers for many years to
come, and such efforts will likely allow us
to harvest some wheat and make a nice,
tasty loaf of bread.
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